Despite the limitations of measles PRN antibody as a biomarker for evidence of measles vaccination in an individual child in areas where wild measles virus is circulating, its use has been advocated in low- and middle-income countries to detect an improvement in community-wide seroprotection after MCV mass immunization campaigns, by performing pre- and post-campaign surveys [23]. The gene discussed is CIAO3; the disease is measles.